Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or greater.~* Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT)~* Corrected visual acuity in each eye equivalent to 20/200 or better~* Able and willing to give signed informed consent and follow study instructions.~Exclusion Criteria:~Ophthalmic:~* Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles.~* Intraocular pressure \>36 mmHg~* Known hypersensitivity to any component of the formulation, latanoprost, or to topical anesthetics.~* Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s)~* Refractive surgery in study eye(s)~* Ocular trauma within the six months prior to screening, or ocular surgery or laser treatment within the three months prior to screening.~* Evidence of ocular infection and inflammation~* Clinically significant ocular disease, which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe~* Central corneal thickness greater then 600 μm~* Any abnormality preventing reliable applanation tonometry of either eye~Systemic:~* Clinically significant abnormalities (as determined by the investigator) in laboratory tests at screening.~* Clinically significant systemic disease~* Participation in any investigational study within 30 days prior to screening~* Changes in systemic medication~* Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PG324 Ophthalmic Solution 0.01% (Type: EXPERIMENTAL): Netarsudil 0.01%, Latanoprost 0.005% fixed combination ophthalmic solution
- PG324 Ophthalmic Solution 0.02% (Type: EXPERIMENTAL): Netarsudil 0.02%, Latanoprost 0.005% fixed combination ophthalmic solution
- Netarsudil (AR-13324) Ophthalmic Solution 0.02% (Type: ACTIVE_COMPARATOR): Netarsudil 0.02% ophthalmic solution
- Latanoprost Ophthalmic Solution 0.005% (Type: ACTIVE_COMPARATOR): Latanoprost 0.005% ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).